Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Inipharm has raised $35 million in series A financing from 5AM Ventures, Wu Capital, and existing investors. Founded in 2018, Inipharm is developing small-molecule drugs that modulate HSD17B13, a gene associated with liver diseases including nonalcoholic steatohepatitis (NASH), which is the target of numerous drug development efforts. Regeneron and Alnylam, for example, are testing RNA interference to combat NASH.
This article has been sent to the following recipient: